<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00570102</url>
  </required_header>
  <id_info>
    <org_study_id>195003</org_study_id>
    <secondary_id>BHM4-CT96-0233</secondary_id>
    <nct_id>NCT00570102</nct_id>
  </id_info>
  <brief_title>Nutritional Prevention Pilot Trial for Type 1 Diabetes</brief_title>
  <acronym>MIP</acronym>
  <official_title>Trial to Reduce IDDM in the Genetically at Risk (TRIGR): the Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Academy of Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Union</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Diabetes Research Foundation, Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Helsinki University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of the study is to assess whether complete avoidance of cow's milk (CM)
      proteins, for at least the first 6 months of life, prevents type 1 diabetes
      (insulin-dependent diabetes mellitus, IDDM) in genetically susceptible children who have a
      mother, biological father or sibling affected by type 1 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Among the environmental factors leading to type 1 diabetes in childhood, the most important
      are certain viral infections and possibly some dietary factors. Among the latter cow's milk
      proteins are of special interest. They have been shown to be involved in the pancreatic
      beta-cell lesion in animal experiments. In humans there are some indications of a role of
      early exposure to cow's milk proteins as a risk factor for later type 1 diabetes. The
      hypothesis has not been confirmed, but a randomized, controlled double-blinded intervention
      trial should provide a definite answer.

      This study aims at assessing whether one can decrease the future incidence of beta-cell
      autoimmunity and/or type 1 diabetes in children who have an increased genetic risk for the
      disease, by administering in infancy after breast feeding until the age of 6-8 months such a
      formula, in which the cow's milk proteins have been hydrolyzed to smaller peptides. The
      children in the control group, carrying a similar increased genetic risk, will receive a
      conventional cow's milk based formula .

      This project is a pilot multicenter trial comprising 15 hospitals in Finland.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 1995</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">March 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positivity for two or more diabetes-associated autoantibodies and/or clinical type 1 diabetes</measure>
    <time_frame>10 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">230</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>A highly hydrolyzed casein formula</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>A conventiona cow's milk based formula</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>A highly hydrolyzed formula</intervention_name>
    <description>Weaning to a highly hydrolyzed formula, avoidance of all supplemental food containing cow's milk proteins and/or bovine serum albumin up to the age of 6-8 months</description>
    <arm_group_label>A highly hydrolyzed casein formula</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>A regular cow's milk based formula</intervention_name>
    <description>Weaning to a regular cow's milk based formula supplemented with 20% of the highly hydrolyzed formula used in arm 1 to make the study formulas similar in smell and taste, avoidance of all supplemental food containing cow's milk proteins and/or bovine serum albumin</description>
    <arm_group_label>A conventiona cow's milk based formula</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  the participant must have a mother, biological father or sibling with type 1 diabetes

          -  the participant must carry a susceptible HLA genotype(HLA-DQB1*02 and/or DQB1*0302
             without protective alleles (DQB1*0301, *0602 and *0603)

        Exclusion Criteria:

          -  no telephone

          -  no accessibility to any of the research centers

          -  inability of parents to understand the study and instructions

          -  unwillingness/inability to feed the infant CM-containing food for any reason (e.g.
             religious, cultural reasons)

          -  gestational age less than 36 weeks

          -  Any severe illness such as chromosomal abnormalities, congenital malformations,
             respiratory failure, enzyme deficiencies of the newborn.

          -  the newborn infant has received any cow's milk-based product prior to randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>7 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans K Åkerlom, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Helsinki, Helsinki, Finland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jorvi Hospital</name>
      <address>
        <city>Espoo</city>
        <zip>02740</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Helsinki, Department of Obstetrics and Gynecology</name>
      <address>
        <city>Helsinki</city>
        <zip>00290</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Public Health Institute</name>
      <address>
        <city>Helsinki</city>
        <zip>00300</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki University Hospital, Maternity Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00610</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Helsinki, Hospital for Children and Adolescents</name>
      <address>
        <city>Helsinki</city>
        <zip>FIN-00290</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanta-Häme Central Hospital, Department of Pediatrics</name>
      <address>
        <city>Hämeenlinna</city>
        <zip>13530</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Karelia Central Hospital</name>
      <address>
        <city>Joensuu</city>
        <zip>80210</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Finland Central Hospital</name>
      <address>
        <city>Jyväskylä</city>
        <zip>40620</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kymenlaakso Central Hospital, Department of Pediatrics</name>
      <address>
        <city>Kotka</city>
        <zip>48210</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kuopio, Department of Pediatrics</name>
      <address>
        <city>Kuopio</city>
        <zip>70210</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Päijät-Häme Central Hospital</name>
      <address>
        <city>Lahti</city>
        <zip>15850</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Karelia Central Hospital</name>
      <address>
        <city>Lappeenranta</city>
        <zip>53130</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oulu, Department of Pediatrics</name>
      <address>
        <city>Oulu</city>
        <zip>90014</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Satakunta Central Hospital</name>
      <address>
        <city>Pori</city>
        <zip>28500</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Ostrobothnia Central Hospital</name>
      <address>
        <city>Seinäjoki</city>
        <zip>60220</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital, Department of Pediatrics</name>
      <address>
        <city>Tampere</city>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Turku, Department of Virology</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vaasa Central Hospital</name>
      <address>
        <city>Vaasa</city>
        <zip>65130</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <link>
    <url>http://trigr.epi.usf.edu</url>
    <description>The TRIGR Study proper tests the hypothesis whether weaning to a highly hydrolyzed formula reduces the cumulative incidence of beta-cell autoimmunity and clinical diabetes in subjects with increased genetic disease susceptibility</description>
  </link>
  <reference>
    <citation>Akerblom HK, Savilahti E, Saukkonen TT, Paganus A, Virtanen SM, Teramo K, Knip M, Ilonen J, Reijonen H, Karjalainen J, et al. The case for elimination of cow's milk in early infancy in the prevention of type 1 diabetes: the Finnish experience. Diabetes Metab Rev. 1993 Dec;9(4):269-78. Review.</citation>
    <PMID>7924824</PMID>
  </reference>
  <reference>
    <citation>Akerblom HK, Knip M. Putative environmental factors in Type 1 diabetes. Diabetes Metab Rev. 1998 Mar;14(1):31-67. Review.</citation>
    <PMID>9605629</PMID>
  </reference>
  <reference>
    <citation>Knip M, Akerblom HK. IDDM prevention trials in progress--a critical assessment. J Pediatr Endocrinol Metab. 1998 Apr;11 Suppl 2:371-7. Review.</citation>
    <PMID>9642667</PMID>
  </reference>
  <reference>
    <citation>Knip M, Akerblom HK. Environmental factors in the pathogenesis of type 1 diabetes mellitus. Exp Clin Endocrinol Diabetes. 1999;107 Suppl 3:S93-100. Review.</citation>
    <PMID>10522815</PMID>
  </reference>
  <reference>
    <citation>Vaarala O, Hyöty H, Akerblom HK. Environmental factors in the aetiology of childhood diabetes. Diabetes Nutr Metab. 1999 Apr;12(2):75-85. Review.</citation>
    <PMID>10554890</PMID>
  </reference>
  <reference>
    <citation>Akerblom HK, Vaarala O, Hyöty H, Ilonen J, Knip M. Environmental factors in the etiology of type 1 diabetes. Am J Med Genet. 2002 May 30;115(1):18-29. Review.</citation>
    <PMID>12116173</PMID>
  </reference>
  <reference>
    <citation>Knip M, Akerblom HK. Early nutrition and later diabetes risk. Adv Exp Med Biol. 2005;569:142-50. Review.</citation>
    <PMID>16137119</PMID>
  </reference>
  <reference>
    <citation>Knip M, Veijola R, Virtanen SM, Hyöty H, Vaarala O, Akerblom HK. Environmental triggers and determinants of type 1 diabetes. Diabetes. 2005 Dec;54 Suppl 2:S125-36. Review.</citation>
    <PMID>16306330</PMID>
  </reference>
  <results_reference>
    <citation>Paronen J, Knip M, Savilahti E, Virtanen SM, Ilonen J, Akerblom HK, Vaarala O. Effect of cow's milk exposure and maternal type 1 diabetes on cellular and humoral immunization to dietary insulin in infants at genetic risk for type 1 diabetes. Finnish Trial to Reduce IDDM in the Genetically at Risk Study Group. Diabetes. 2000 Oct;49(10):1657-65.</citation>
    <PMID>11016449</PMID>
  </results_reference>
  <results_reference>
    <citation>Hämäläinen AM, Ronkainen MS, Akerblom HK, Knip M. Postnatal elimination of transplacentally acquired disease-associated antibodies in infants born to families with type 1 diabetes. The Finnish TRIGR Study Group. Trial to Reduce IDDM in the Genetically at Risk. J Clin Endocrinol Metab. 2000 Nov;85(11):4249-53.</citation>
    <PMID>11095462</PMID>
  </results_reference>
  <results_reference>
    <citation>Ronkainen MS, Hämäläinen AM, Koskela P, Akerblom HK, Knip M; Finnish Trigr Study Group. Pregnancy induces nonimmunoglobulin insulin-binding activity in both maternal and cord blood serum. Clin Exp Immunol. 2001 May;124(2):190-6.</citation>
    <PMID>11422194</PMID>
  </results_reference>
  <results_reference>
    <citation>Hämäläinen AM, Savola K, Kulmala PK, Koskela P, Akerblom HK, Knip M; Finnish TRIGR Study Group. Disease-associated autoantibodies during pregnancy and at birth in families affected by type 1 diabetes. Clin Exp Immunol. 2001 Nov;126(2):230-5.</citation>
    <PMID>11703365</PMID>
  </results_reference>
  <results_reference>
    <citation>Sadeharju K, Hämäläinen AM, Knip M, Lönnrot M, Koskela P, Virtanen SM, Ilonen J, Akerblom HK, Hyöty H; Finnish TRIGR Study Group. Enterovirus infections as a risk factor for type I diabetes: virus analyses in a dietary intervention trial. Clin Exp Immunol. 2003 May;132(2):271-7.</citation>
    <PMID>12699416</PMID>
  </results_reference>
  <results_reference>
    <citation>Akerblom HK, Virtanen SM, Ilonen J, Savilahti E, Vaarala O, Reunanen A, Teramo K, Hämäläinen AM, Paronen J, Riikjärv MA, Ormisson A, Ludvigsson J, Dosch HM, Hakulinen T, Knip M; National TRIGR Study Groups. Dietary manipulation of beta cell autoimmunity in infants at increased risk of type 1 diabetes: a pilot study. Diabetologia. 2005 May;48(5):829-37. Epub 2005 Apr 19. Erratum in: Diabetologia. 2005 Aug;48(8):1676. Riikjärv, MA [added]; Ormisson, A [added]; Ludvigsson, J [added]; Dosch, HM [added]; Hakulinen, T [added]; Knip, M [added].</citation>
    <PMID>15838685</PMID>
  </results_reference>
  <results_reference>
    <citation>Tiittanen M, Paronen J, Savilahti E, Virtanen SM, Ilonen J, Knip M, Akerblom HK, Vaarala O; Finnish TRIGR Study Group. Dietary insulin as an immunogen and tolerogen. Pediatr Allergy Immunol. 2006 Nov;17(7):538-43.</citation>
    <PMID>17014631</PMID>
  </results_reference>
  <results_reference>
    <citation>Sadeharju K, Knip M, Virtanen SM, Savilahti E, Tauriainen S, Koskela P, Akerblom HK, Hyöty H; Finnish TRIGR Study Group. Maternal antibodies in breast milk protect the child from enterovirus infections. Pediatrics. 2007 May;119(5):941-6.</citation>
    <PMID>17473095</PMID>
  </results_reference>
  <results_reference>
    <citation>Knip M, Virtanen SM, Seppä K, Ilonen J, Savilahti E, Vaarala O, Reunanen A, Teramo K, Hämäläinen AM, Paronen J, Dosch HM, Hakulinen T, Akerblom HK; Finnish TRIGR Study Group. Dietary intervention in infancy and later signs of beta-cell autoimmunity. N Engl J Med. 2010 Nov 11;363(20):1900-8. doi: 10.1056/NEJMoa1004809.</citation>
    <PMID>21067382</PMID>
  </results_reference>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2007</study_first_submitted>
  <study_first_submitted_qc>December 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2007</study_first_posted>
  <last_update_submitted>November 27, 2012</last_update_submitted>
  <last_update_submitted_qc>November 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University</investigator_affiliation>
    <investigator_full_name>Mikael Knip</investigator_full_name>
    <investigator_title>Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>dietary manipulation</keyword>
  <keyword>infants</keyword>
  <keyword>feasibility</keyword>
  <keyword>Type 1 Diabetes Mellitus, Beta-cell Autoimmunity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

